| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,740 | 13,942 | 12:04 | |
| 13,740 | 13,942 | 12:04 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 14,398 | 880 | |||
| 14,356 | 834 | |||
| 14,342 | 622 | |||
| 14,142 | 1.740 | |||
| 14,058 | 712 | |||
| 14,050 | 539 | |||
| 14,036 | 2 | |||
| 14,000 | 2 | |||
| 13,998 | 199 | |||
| 13,996 | 1.221 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/via.htm [/URL] | ||||
| 973 | 13,686 | |||
| 400 | 13,656 | |||
| 733 | 13,654 | |||
| 539 | 13,642 | |||
| 2 | 13,630 | |||
| 834 | 13,532 | |||
| 1.740 | 13,330 | |||
| 622 | 13,242 | |||
| 880 | 13,006 | |||
| 100 | 13,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 6.823 | 0,989 | 6.751 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 10.06.2026 | 10:00:15 | 13,910 | 218 |
| 10.06.2026 | 10:00:15 | 13,910 | 300 |
| 10.06.2026 | 09:04:49 | 13,744 | 7 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VIATRIS Aktie jetzt für 0€ handeln | |||||
| 22.05. | Dividendenbekanntmachungen (22.05.2026) | 20.559 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| 18.05. | Here's Why Viatris (VTRS) is a Strong Momentum Stock | 51 | Zacks | ||
| 18.05. | Viatris's NDA For MR-107A-02 Secures FDA Acceptance | 458 | AFX News | WASHINGTON (dpa-AFX) - Monday, Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for MR-107A-02 for the treatment of moderate-to-severe... ► Artikel lesen | |
| 18.05. | FDA accepts Viatris application for fast-acting meloxicam | 10 | Investing.com | ||
| 18.05. | Viatris Inc.: U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain | 806 | PR Newswire | FDA PDUFA Goal Date Set for Dec. 27, 2026
PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 11:15 | Dividendenbekanntmachungen (11.06.2026) | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADT INC US00090Q1031 0,055 USD 0,0476 EUR ALAMOS GOLD INC CA0115321089 0,04 USD 0,0346 EUR ALPINE INCOME PROPERTY TRUST INC US02083X1037 0... ► Artikel lesen | |
| 07:10 | F. Hoffmann-La Roche Ltd: FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer | GlobeNewswire (Europe) | Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone1Nearly one in three patients with... ► Artikel lesen | |
| 10:15 | Novo Nordisk Aktie: Schimmer der Hoffnung | 4investors | Die Novo Nordisk Aktie ist seit Mitte 2024 in mehreren starken Verkaufswellen tief gefallen, doch inzwischen mehren sich die Anzeichen, dass sie sich gefangen haben könnte. Seit dem Tief Anfang März... ► Artikel lesen | |
| 07:26 | Cosmo Pharmaceuticals N.V.: Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark | Newsfile | Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) ("Cosmo") is pleased to make known that its commercial partner Glenmark Specialty S.A (GSSA), a wholly-owned... ► Artikel lesen | |
| 07:10 | Novartis Pharma AG: Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint | GlobeNewswire (Europe) | Ad hoc announcement pursuant to Art. 53 LR
FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous... ► Artikel lesen |